In the present study, apigenin markedly decreased plasma total-cholesterol levels, as well as plasma apoB levels and the apoB/apoA1 ratio, indicating its protective role against atherogenic dyslipidemia in HFD-induced obese mice. This evidence concerns the gene APOB and metabolic syndrome.